Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Given Average Recommendation of “Hold” by Brokerages

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $31.60.

A number of equities research analysts recently issued reports on the company. Bank of America raised their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 26th. Needham & Company LLC upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a research report on Tuesday, August 12th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating for the company in a research report on Friday, August 8th.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $23.86 on Wednesday. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $1.11 billion, a PE ratio of 8.94 and a beta of 0.75. Amphastar Pharmaceuticals has a 12-month low of $20.39 and a 12-month high of $53.96. The firm has a 50-day moving average price of $27.78 and a 200-day moving average price of $25.35.

Hedge Funds Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Amphastar Pharmaceuticals by 5.2% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,440 shares of the company’s stock worth $217,000 after acquiring an additional 465 shares in the last quarter. Hohimer Wealth Management LLC raised its holdings in Amphastar Pharmaceuticals by 6.9% in the first quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company’s stock worth $232,000 after purchasing an additional 520 shares in the last quarter. Signaturefd LLC raised its holdings in Amphastar Pharmaceuticals by 147.7% in the first quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after purchasing an additional 520 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Amphastar Pharmaceuticals by 13.8% in the first quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company’s stock worth $139,000 after purchasing an additional 580 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.